Disease · MONDO_0000922

pelvic inflammatory disease

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. pelvic inflammatory disease. Diseases, record MONDO_0000922. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0000922

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: pelvic inflammatory disease; Open Targets
Open Targets ID: MONDO_0000922; Open Targets
Other names: PID; Open Targets
Disease Ontology: DOID:1003; Disease Ontology
MeSH: D000292; MeSH
NCI Thesaurus: C3889; NCI Thesaurus
Highest stage of its drugs: Approval, for 4 of its 16 drugs, from DailyMed and PMDA; Open Targets

Drugs16

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CEFTRIAXONE SODIUM	CHEMBL6067656	Small molecule	Approval	DailyMed and PMDA	3	1	1	Drugs and targets
AZITHROMYCIN	CHEMBL529	Small molecule	Approval	DailyMed	2	1	1	Drugs and targets
PIPERACILLIN SODIUM	CHEMBL1200820	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
TAZOBACTAM SODIUM	CHEMBL1439	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
METRONIDAZOLE	CHEMBL137	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
MOXIFLOXACIN	CHEMBL32	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
LEVOFLOXACIN	CHEMBL5315124	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
OFLOXACIN	CHEMBL4	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
DOXYCYCLINE	CHEMBL1200699	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
CEFTRIAXONE	CHEMBL161	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 16

See all 16 drugs

Targets4

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
MMP1	Interstitial collagenase	2	Matrix metalloproteinase-1 inhibitor	Phase 2	https://conductscience.org/library/genes/4312	Drugs and targets
MMP13	Collagenase 3	2	Matrix metalloproteinase 13 inhibitor	Phase 2	https://conductscience.org/library/genes/4322	Drugs and targets
MMP7	Matrilysin	2	Matrix metalloproteinase 7 inhibitor	Phase 2	https://conductscience.org/library/genes/4316	Drugs and targets
MMP8	Neutrophil collagenase	2	Matrix metalloproteinase 8 inhibitor	Phase 2	https://conductscience.org/library/genes/4317	Drugs and targets

Trials7

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00453349	A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease	Phase 3	460	2009-11-30	Pelvic Inflammatory Disease	LEVOFLOXACIN, METRONIDAZOLE, MOXIFLOXACIN	Its record names the disease	ClinicalTrials.gov
NCT01160640	The Importance of Anti-anaerobic Therapy for Acute Pelvic Inflammatory Disease (PID)	Phase 2	233	2016-12-21	Pelvic Inflammatory Disease	CEFTRIAXONE, DOXYCYCLINE, METRONIDAZOLE	Its record names the disease	ClinicalTrials.gov
NCT00871494	Study Of Azithromycin Intravenous Formulation Against Pelvic Inflammatory Disease (PID) In Japan	Phase 3	76	2011-11-03	Pelvic Inflammatory Disease	AZITHROMYCIN	Its record names the disease	ClinicalTrials.gov
NCT01473836	A Phase 3 Study Of Intravenous Metronidazole For Intrabdominal Infection	Phase 3	38	2013-12-10	Intra-abdominal Infections	CEFTRIAXONE SODIUM, METRONIDAZOLE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT01434173	Risk of Acute Liver Injury in Users of Antimicrobials		1,299,056		Drug-Induced Liver Injury	AMOXICILLIN, CEFUROXIME, CLARITHROMYCIN, CLAVULANIC ACID, DOXYCYCLINE, LEVOFLOXACIN, MOXIFLOXACIN, TELITHROMYCIN	Its record names the disease	ClinicalTrials.gov
NCT00683865	Uncomplicated Pelvic Inflammatory Disease. Treatment With Moxifloxacin.	Phase 3	749		Pelvic Inflammatory Disease	METRONIDAZOLE, MOXIFLOXACIN, OFLOXACIN	Its record names the disease	ClinicalTrials.gov
NCT04723069	Efficacy and Safety of Fuke Qianjin Capsule in Patients With Pelvic Inflammatory Diseases	Phase 2	198		Pelvic Inflammatory Disease	DOXYCYCLINE HYCLATE, METRONIDAZOLE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Moxifloxacin vs Levofloxacin Plus Metronidazole: serious adverse events	3 of 225	1 of 230	455	NCT00453349	Trial comparisons
Ceftriaxone, Doxycycline, Metronidazole vs Ceftriaxone, Doxycycline, Placebo: serious adverse events	7 of 116	5 of 117	233	NCT01160640	Trial comparisons

Papers from its trials5

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
20716255	RESULT	1	PubMed
38584600	DERIVED	1	PubMed
32052831	DERIVED	1	PubMed
25442806	DERIVED	1	PubMed
24787738	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0000922

GET https://conductscience.org/api/diseases/v1/MONDO_0000922/drugs

API reference For AI assistants